Skip to content

Iloperidone

FDA-approved product (tablet, oral), marketed as Fanapt, Iloperidone.

Registered studies
32
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Iloperidone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Psychosis
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antipsychotics
FDA pharmacologic class
Atypical Antipsychotic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli45.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae44.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

32registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Iloperidone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Elpipodect (MK-8189) Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)

    NCT02181803 · start 2014-08-05

    Registered record
    Registry ID
    NCT02181803
    Conditions
    Schizophrenia
    Interventions
    Elpipodect; Placebo; Base Monotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-08-05
    Completion
    2015-04-23
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionElpipodect; Placebo; Base Monotherapy
    PhasePhase 1
    Registry statusCompleted
  • Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia

    NCT02453893 · start 2013-11

    Registered record
    Registry ID
    NCT02453893
    Conditions
    Schizophrenia
    Interventions
    Iloperidone; Risperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2013-11
    Completion
    Not recorded
    Enrolment
    288

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionIloperidone; Risperidone
    PhasePhase 3
    Registry statusUnknown
  • Iloperidone for Symptoms of Arousal in Post Traumatic Stress Disorder (PTSD)

    NCT01917318 · start 2013-07

    Registered record
    Registry ID
    NCT01917318
    Conditions
    Post Traumatic Stress Disorder
    Interventions
    Iloperidone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-07
    Completion
    2014-02
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost Traumatic Stress Disorder
    InterventionIloperidone; Placebo
    PhasePhase 2
    Registry statusTerminated
  • An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)

    NCT01498770 · start 2013-04-01

    Registered record
    Registry ID
    NCT01498770
    Conditions
    Bipolar Disorder
    Interventions
    Asenapine; Aripiprazole; Quetiapine; Risperidone; Olanzapine; Ziprasidone; Iloperidone; Paliperidone; Lurasidone; Clozapine; Amisulpride; Sertindole; Zotepine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-04-01
    Completion
    2017-12-21
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder
    InterventionAsenapine; Aripiprazole; Quetiapine; Risperidone +9 more
    PhaseNot recorded
    Registry statusCompleted
  • Assessment and Comparison of Metabolic Changes in Non-psychotic Adults Taking Iloperidone or Olanzapine or Placebo

    NCT01920802 · start 2012-11

    Registered record
    Registry ID
    NCT01920802
    Conditions
    Healthy
    Interventions
    olanzapine; iloperidone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-11
    Completion
    2014-09
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionolanzapine; iloperidone; Placebo
    PhasePhase 4
    Registry statusCompleted
  • Cross-Sectional Iloperidone IVGTT

    NCT01686815 · start 2012-10

    Registered record
    Registry ID
    NCT01686815
    Conditions
    Schizophrenia; Serious Mental Illness; Metabolic Syndrome; Insulin Resistance; Glucose Metabolism
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-10
    Completion
    2016-05
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Serious Mental Illness; Metabolic Syndrome; Insulin Resistance +1 more
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted
  • Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia

    NCT01623713 · start 2012-06

    Registered record
    Registry ID
    NCT01623713
    Conditions
    Schizophrenia; Iloperidone; Efficacy
    Interventions
    iloperidone; Risperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-06
    Completion
    2013-11
    Enrolment
    260

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Iloperidone; Efficacy
    Interventioniloperidone; Risperidone
    PhasePhase 2
    Registry statusCompleted
  • Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability

    NCT01464229 · start 2012-04

    Registered record
    Registry ID
    NCT01464229
    Conditions
    Major Depressive Disorder
    Interventions
    Iloperidone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-04
    Completion
    2014-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionIloperidone; Placebo
    PhasePhase 4
    Registry statusCompleted
  • Assessing the Effects of Fanapt® on Social Cognition in Schizophrenia

    NCT01929889 · start 2012-04

    Registered record
    Registry ID
    NCT01929889
    Conditions
    Schizophrenia; Schizoaffective Disorder
    Interventions
    Iloperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2012-04
    Completion
    2014-10
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder
    InterventionIloperidone
    PhasePhase 4
    Registry statusTerminated
  • Iloperidone in Mixed States of Bipolar Disorder

    NCT02413918 · start 2012-04

    Registered record
    Registry ID
    NCT02413918
    Conditions
    Bipolar Disorder
    Interventions
    iloperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-04
    Completion
    2015-04
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder
    Interventioniloperidone
    PhasePhase 4
    Registry statusCompleted
  • Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients

    NCT01495169 · start 2011-10

    Registered record
    Registry ID
    NCT01495169
    Conditions
    Safety and Tolerability of Iloperidone
    Interventions
    iloperidone (oral tablet)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-10
    Completion
    2015-02
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSafety and Tolerability of Iloperidone
    Interventioniloperidone (oral tablet)
    PhasePhase 1
    Registry statusCompleted
  • Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients

    NCT01348100 · start 2011-04

    Registered record
    Registry ID
    NCT01348100
    Conditions
    Schizophrenia
    Interventions
    Iloperidone crystalline formulation; Iloperidone microparticle formulation; Oral iloperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2011-04
    Completion
    2012-07
    Enrolment
    81

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionIloperidone crystalline formulation; Iloperidone microparticle formulation; Oral iloperidone
    PhasePhase 1 / Phase 2
    Registry statusCompleted
  • Relapse Prevention Study in Patients With Schizophrenia

    NCT01291511 · start 2011-02

    Registered record
    Registry ID
    NCT01291511
    Conditions
    Schizophrenia
    Interventions
    Iloperidone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-02
    Completion
    2015-03
    Enrolment
    635

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionIloperidone; Placebo
    PhasePhase 3
    Registry statusCompleted
  • Switching to Iloperidone From Other Antipsychotics in Schizophrenia

    NCT01207414 · start 2010-08

    Registered record
    Registry ID
    NCT01207414
    Conditions
    Schizophrenia
    Interventions
    iloperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-08
    Completion
    2012-01
    Enrolment
    501

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventioniloperidone
    PhasePhase 4
    Registry statusCompleted
  • Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared to Healthy Volunteers

    NCT01529294 · start 2010-08

    Registered record
    Registry ID
    NCT01529294
    Conditions
    Hepatic Impairment
    Interventions
    Iloperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-08
    Completion
    2012-07
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Impairment
    InterventionIloperidone
    PhasePhase 1
    Registry statusCompleted